来源:药渡撰文:Pharmadeep编辑:维他命2025年6月16日,中国ADC赛道迎来重磅合作——先声药业旗下先声再明与美国生物制药公司NextCure宣布就靶向CDH6的ADC新药SIM0505达成全球战略合作,潜在交易总额达7.45亿美元。更值得关注的是,此次合作实现了中国ADC技术平台又一次向发达市场的反向输出,标志着本土创新药企技术授权模式获国际认可。图1. 先声药业官方声明,来源:...
Source Link来源:药渡撰文:Pharmadeep编辑:维他命2025年6月16日,中国ADC赛道迎来重磅合作——先声药业旗下先声再明与美国生物制药公司NextCure宣布就靶向CDH6的ADC新药SIM0505达成全球战略合作,潜在交易总额达7.45亿美元。更值得关注的是,此次合作实现了中国ADC技术平台又一次向发达市场的反向输出,标志着本土创新药企技术授权模式获国际认可。图1. 先声药业官方声明,来源:...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.